Novo Nordisk Launches Weekly Insulin Awiqli in India

Novo Nordisk has launched its weekly insulin product Awiqli in India in response to the growing diabetes burden. This move is part of the company's strategy to offer innovative solutions in diabetes treatment. Awiqli aims to improve treatment adherence for type 2 diabetes patients by reducing the need for daily injections. India stands out as one of the countries with the highest number of diabetes patients globally. Approximately 77 million adults in the country live with diabetes, and this number is expected to rise further in the coming years. Novo Nordisk's initiative creates a market opportunity targeting both the existing patient population and potential new patients. The launch of Awiqli reflects the company's efforts to expand its global diabetes drug portfolio. As a once-weekly insulin analog, the product aims to enhance patients' quality of life. With this launch, Novo Nordisk seeks to gain a competitive advantage in the Indian market. This is not investment advice.